60 Degrees Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
60 Degrees Pharmaceuticals has been growing earnings at an average annual rate of 1.1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 2.6% per year.
Key information
1.1%
Earnings growth rate
96.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 2.6% |
| Return on equity | -11.1% |
| Net Margin | -194.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How 60 Degrees Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -1 | 5 | 0 |
| 31 Dec 23 | 0 | -4 | 4 | 0 |
| 30 Sep 23 | 0 | -4 | 3 | 0 |
| 30 Jun 23 | 0 | -9 | 2 | 0 |
| 31 Mar 23 | 0 | -8 | 2 | 0 |
| 31 Dec 22 | 1 | -6 | 1 | 0 |
| 30 Sep 22 | 1 | -6 | 1 | 0 |
| 31 Dec 21 | 6 | -4 | 1 | 0 |
| 31 Dec 20 | 3 | -3 | 1 | 0 |
Quality Earnings: SXTP is currently unprofitable.
Growing Profit Margin: SXTP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SXTP is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare SXTP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SXTP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).
Return on Equity
High ROE: SXTP has a negative Return on Equity (-11.06%), as it is currently unprofitable.